Fundraising FoxPeloton Therapeutics
Unicorn exit · $2.2Bacquired by Merck6 known investors
Find your way into Peloton Therapeutics
Sign up to see every warm intro you have to Peloton Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Peloton Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Merck May 2019 · $2.2B (up to $2.2 billion ($1.05B upfront cash, $1.15B contingent milestones)) · source ↗
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
Investors · 6
How we know: Curative Ventures's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Nextech Invest's portfolio page · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: The Column Group's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Vida Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Peloton Therapeutics do?
- Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
- Who are Peloton Therapeutics's investors?
- Peloton Therapeutics's investors include Curative Ventures, Foresite Capital, Nextech Invest, Ridgeback Capital, The Column Group, Vida Ventures.
- Who acquired Peloton Therapeutics?
- Peloton Therapeutics was acquired by Merck.